The short version of albumin binding fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-06-18. Anything still debated is marked as such rather than presented as settled.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 or 280 nanometres is widely used to assess purity and to resolve related impurities. Liquid chromatography coupled to mass spectrometry confirms identity through the protonated molecular ion and fragment ions formed in tandem experiments. Capillary electrophoresis and peptide mapping after enzymatic digestion supply complementary information on charge variants and modification sites. Circular dichroism and nuclear magnetic resonance can report on secondary structure in solution. Absolute quantification usually depends on an external standard, and reported purity depends on the detection wavelength and integration parameters chosen.
Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.
Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.
| Property | Value | Notes |
|---|---|---|
| Molecular class | 31-amino-acid peptide | Modified glucagon-like peptide-1 analogue |
| Molecular mass | approximately 4114 Da | Calculated for the free peptide backbone |
| Appearance | white to off-white powder | Typical of purified lyophilised peptide batches |
| Solubility class | freely soluble in water | Aqueous solubility improves at slightly alkaline pH |
| Typical storage | -20 degrees Celsius, dry, dark | Protect from repeated freeze-thaw cycles |
序列层面的改动同时解决了两个问题，即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟，主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库，使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发，属于该类药物化学改造的典型范式。
Semaglutide 是一种经结构修饰的胰高血糖素样肽-1 类似物，其主链与内源性 GLP-1(7-36) 约有百分之九十四的序列一致性。第 8 位丙氨酸被 α-氨基异丁酸取代，使二肽基肽酶-4 无法识别原有切割位点。第 34 位赖氨酸换为精氨酸，进一步降低酶解速率。第 26 位赖氨酸经间隔基连接一条含十八个碳的二酸脂肪链，该侧链赋予分子与血浆白蛋白结合的能力。
该分子作为 GLP-1 受体的选择性激动剂发挥作用，受体属于 B 类 G 蛋白偶联受体家族，激活后经 Gs 通路提升细胞内环腺苷酸水平。在胰腺 β 细胞，信号促进葡萄糖依赖性的胰岛素释放，血糖偏低时该作用明显减弱。在胰岛 α 细胞，胰高血糖素分泌受到抑制。中枢神经系统与胃肠道同样存在受体表达，相应信号参与食欲调节以及胃排空速率的降低。
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Bulk pharmaceuticals can be shipped to another pharmaceutical company for further processing, to a contract packager for forming unit packs, to international customers, etc. Bulk shipments might be in fiber drums (with plastic liners), bulk boxes, corrugated boxes with liners, intermediate bulk containers, and other shipping containers. Smaller bulk packs can be shipped to pharmacies, particularly compounding pharmacies. The liquids or powders can be measured and put into primary packages. Shipments to medical professionals could be at hospitals, nursing homes, veterinarians, dentists, etc. These packaged pharmaceuticals are intended to be dispensed and administered by professionally trained and certified personnel.
=== Effect of altering the peptide structure on anti-phalloidin activity === It has been shown that altering any of the proline residues reduces the inhibitory activity to zero. In addition, altering the phenylalanine residues to tyrosine or L-cyclohexylalanine also reduces the activity to zero.
=== Grey market use === Suvomipic has attracted an unusual amount of attention for an investigational drug, such as in the r/Tressless subreddit about hair loss on Reddit. A large group of r/Tressless members, having believed that JXL069 is suvomipic, are known to have sourced JXL069 from China in 2025 in an effort to treat their hair loss. This included sending a sample to an analytical testing lab to confirm the compound's authenticity. Pelage Pharmaceuticals says that it does not endorse such use and has explicitly stated that suvomipic is not JXL069. Suvomipic is also said to not be JXL082. In July 2026, the INNTooltip International Nonproprietary Name of suvomipic was published and revealed that suvomipic is in fact JXL069.
Alport syndrome is a rare genetic disorder, characterized by glomerulonephritis, end-stage kidney disease, and hearing loss. Alport syndrome can also affect the eyes, though the changes do not usually affect vision, except when changes to the lens occur in later life. Blood in urine is universal. Proteinuria is a feature as kidney disease progresses. The disorder was first identified in a British family by the physician Cecil A. Alport in 1927. Alport syndrome once also had the label hereditary nephritis, but this is misleading as there are many other causes of hereditary kidney disease and 'nephritis'. Alport syndrome is caused by an inherited defect in type IV collagen—a structural material needed for the normal function of different body parts. Since type IV collagen is found in the ears, eyes, and kidneys, this explains why Alport syndrome affects different seemingly unrelated parts of the body (ears, eyes, kidneys, etc.). Depending on where the mutation is located in the genome, Alport syndrome can present itself in many forms. This includes X-linked Alport syndrome (XLAS), autosomal recessive Alport syndrome (ARAS), and autosomal dominant Alport syndrome (ADAS).
She played the role of Amelia Slater in the Fox series Pitch, about Ginny Baker (Kylie Bunbury), a young black woman who makes history by becoming the first woman to play for a Major League Baseball team. The series ran for a season, which was released in 2016. From 2019 to 2020, Larter acted in the recurring role of Grace Sawyer in the police procedural series The Rookie on ABC In 2021, she played the lead role in the neo-western film The Last Victim. She starred in the thriller The Man in the White Van, which premiered at the 2023 Newport Beach Film Festival and was released in December 2024 to mixed reviews. In 2024, Larter co-starred in Taylor Sheridan’s show Landman, starring Billy Bob Thornton. Larter plays Angela Norris, a “cartoonish” funny caricature of a gold-digging ex-wife.
Sources: en.wikipedia.org
=== Acquisition and expansion (2017–2025) === In late July 2017, the Chinese Room's directors, Dan Pinchbeck and Jessica Curry, laid off the entire staff—at that point eight people—and ditched their Brighton office for home. They cited the lack of ability to pay their staff during the interim between projects as the reason for the closure, and expressed their intentions that the studio itself was still running without the development team, with Pinchbeck and Curry working on prototyping and acquiring funds on their own time. The company released a VR game, So Let Us Melt, for Google Daydream in September, which was the final project of the former studio. At the time, Pinchbeck, Curry, and Andrew Crawshaw were working alone on the studio's next project, 13th Interior, which was to push away from the "walking simulator" model the studio had been known for. In August 2018, Sumo Group, the parent company of Sumo Digital, acquired the Chinese Room for £2.2 million, making it the fourth UK-based studio under Sumo Digital. Co-founder Pinchbeck took the role of creative director for the Chinese Room, while Curry continued as an independent composer for the studio. Pinchbeck described the acquisition as "the end of a chapter" for the studio as they determined their next project. From late summer 2018, the Chinese Room began re-staffing, adding veteran developers Ed Daly as studio director and John McCormack as art director. Dear Esther launched on iOS on 30 September 2019. On 12 June 2020 the Chinese Room released its first Apple Arcade game, Little Orpheus, to positive reviews.
Dapagliflozin/saxagliptin/metformin, sold under the brand name Qternmet XR among others, is a fixed-dose combination anti-diabetic medication used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. It is a combination of dapagliflozin, saxagliptin, and metformin. It is taken by mouth. The drug is marketed by AstraZeneca. The most common side effects include infections of the nose and throat, hypoglycaemia (low blood sugar) when used with a sulphonylurea and effects on the gut such as nausea (feeling sick), vomiting, diarrhoea, abdominal (tummy) pain and loss of appetite. Dapagliflozin/saxagliptin/metformin was approved for medical use in the United States in May 2019, and in the European Union in November 2019. Its marketing authorisation was withdrawn in the European Union in August 2020, and its approval was withdrawn in the US in April 2021, in both cases at the request of AstraZeneca.
A December 2009 cable between Sanaa and various intelligence agencies in the US diplomatic cables leak states that US State Dept. analysts believed the Houthis obtained weapons from the Yemeni black market and corrupt members of the Yemenis Republican Guard. On the edition of 8 April 2015 of PBS Newshour, Secretary of State John Kerry stated that the US knew Iran was providing military support to the Houthi rebels in Yemen, adding that Washington "is not going to stand by while the region is destabilised". Phillip Smyth of the Washington Institute for Near East Policy told Business Insider that Iran views Shia groups in the Middle East as "integral elements to the Islamic Revolutionary Guard Corps (IRGC)". Smyth claimed that there is a strong bond between Iran and the Houthi uprising working to overthrow the government in Yemen. According to Smyth, in many cases Houthi leaders go to Iran for ideological and religious education, and Iranian and Hezbollah leaders have been spotted on the ground advising the Houthi troops, and these Iranian advisers are likely responsible for training the Houthis to use the type of sophisticated guided missiles fired at the US Navy. To some commentators (e.g., Alex Lockie of Business Insider), Iran's support for the revolt in Yemen is "a good way to bleed the Saudis", a recognized regional and ideological rival of Iran. Essentially, from that perspective, Iran is backing the Houthis to fight against a Saudi-led coalition of Gulf States whose aim is to maintain control of Yemen.
There are three types of non-medical therapies, namely shielding by external protectors, light therapy and acupuncture. Bacterial invasion can be successfully blocked by external protectors of the nipple such as nipple shield, polyethylene film and silver cap, especially when the nipple is impaired by trauma. These protectors create a humid environment for wound recovery while defending it against bacterial infections. The silver cap consists of silver which is a natural agent with antibacterial properties. Hence it is also less likely to cause irritation. Light therapy including phototherapy and low-intensity laser therapy can treat nipple trauma as well. In the range of 630 to 1000 nm wavelength, light therapy facilitates wound recovery by promoting fibroblast proliferation, collagen synthesis, angiogenesis and growth factor production. Moreover, it can stimulate tissue regeneration, accelerate local blood flow rate through vasodilation, suppress inflammation, increase fissure healing rate, and reduce pain sensation. Recently, many review articles have suggested the effectiveness of acupuncture in treating nipple pain as it showed considerable improvement in treating breast engorgement. A 2016 Cochrane review found that a number of interventions were somewhat effective, such as hot/cold packs, Gua-Sha (scraping therapy), cabbage leaves, and proteolytic enzymes but none of the evidence supported widespread implementation.
The talks came close to achieving an overall breakthrough on nuclear arms control, but ended in failure due to Reagan's proposed Strategic Defense Initiative and Gorbachev's proposed cancellation of it. Like Reagan, British Prime Minister Margaret Thatcher also got along well with Gorbachev despite her pronounced anticommunism; she was subsequently encouraged by both his optimistic domestic reform agenda and his arms-control efforts through the mid-1980s. Fundamental to the dissolution of the Soviet Union, the Gorbachev policy initiatives of "restructuring" (perestroika) and "openness" (glasnost) had broad ramifications. To this end, historian Sheila Fitzpatrick wrote of glasnost:
Sources: en.wikipedia.org
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.
No. It shares high sequence identity but carries non-natural modifications that alter its stability and clearance. The naturally occurring hormone is broken down within minutes, while the synthetic analogue circulates far longer.
Attachment to serum albumin reduces renal filtration of the peptide and shields it from enzymatic breakdown. The consequence is a much longer interval between administrations than unmodified peptides allow. The precise contribution of binding affinity to overall duration is still being quantified.
Filtering removes particulate matter that can block columns or scatter light. A 0.22 micrometre membrane is typical, and the filter material should be checked for peptide adsorption.